Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2017 Jul 18;59(4):813–820. doi: 10.1080/10428194.2017.1349907

Table 3.

Response rates by treatment arm.

Best response CIA n (%) FIA n (%) p
CR 13 (27) 8 (24) .77
CRp 5 (10) 2 (6)
CR + CRp 18 (38) 10 (30) .50
HI 4 (8) 2 (6)
PR 1 (3) 0
No response 24 (50) 19 (56)
Early death 5 (10) 4 (12)

CIA: clofarabine, idarubicin, and cytarabine; FIA: fludarabine, idarubicin, and cytarabine; CR: complete remission; CRp: complete remission without platelet recovery; PR: partial remission.